Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BOS-580 by Boston Pharmaceuticals for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
BOS-580 is under clinical development by Boston Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...